An Investigational Study to Evaluate the Effects of Experimental Medication BMS-986256 in Healthy Participants
NCT ID: NCT03634995
Last Updated: 2020-06-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
118 participants
INTERVENTIONAL
2018-08-14
2019-10-09
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of Experimental Medication BMS-986235 in Healthy Subjects
NCT03335553
A Study to Evaluate the Safety, Tolerability and Drug Levels of BMS-986447 in Healthy Participants
NCT05760937
A Study to Evaluate the Safety, Tolerability and Drug Levels of BMS-986454 in Healthy Participants
NCT06086886
A Study of Experimental Medication BMS-986278 Given to Healthy Participants
NCT03429933
Study to Evaluate the Safety, Tolerability, Drug Levels and Drug Effects of BMS-986331 in Healthy Participants
NCT04444050
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Single Dose
Ascending single doses of BMS-986256
BMS-986256
Specified dose on specified days
Placebo
Specified dose on specified days
Multiple Dose
Ascending multiple doses of BMS-986256
BMS-986256
Specified dose on specified days
Placebo
Specified dose on specified days
Sequential Dose
Sequential multiple doses of BMS-986256
BMS-986256
Specified dose on specified days
Placebo
Specified dose on specified days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
BMS-986256
Specified dose on specified days
Placebo
Specified dose on specified days
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Participants must not be current users (within 6 months before screening) of tobacco or tobacco- or nicotine-containing products; they must also be willing to refrain from using any of these products during their participation in the study
* A negative QuantiFERON®-TB Gold test result at screening or documentation of a negative result within 3 months before screening
Exclusion Criteria
* Inability to tolerate oral medication
* Inability to tolerate venipuncture, or inadequate venous access
18 Years
55 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bristol-Myers Squibb
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bristol-Myers Squibb
Role: STUDY_DIRECTOR
Bristol-Myers Squibb
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Anaheim Clinical Trials
Anaheim, California, United States
PRA Health Science KK
Lenexa, Kansas, United States
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
BMS Clinical Trial Information
BMS Clinical Trial Patient Recruiting
Investigator Inquiry Form
FDA Safety Alerts and Recalls
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2017-003729-13
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
IM026-002
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.